Transcreener ADP Assay Enables Evaluation of NIK Inhibitors in Lupus Drug Discovery

Lupus NIK Inhibitor
  Systemic lupus erythematosus (SLE), or lupus, takes a devastating toll. An autoimmune disease that triggers a dysfunctional immune system to attack its own tissues, SLE strikes young women most often — about 4 to 12 times more frequently than men — with women aged 15 to 45 being at highest risk. Both genetic and
Read more
No Comments

Acetyl-CoA Carboxylase Inhibitors: Transcreener ADP Assay Powers Drug Detection Strategy

Acetyl CoA Carboxylase Inhibitors
The impact of Acetyl-CoA carboxylases (ACCs) on eukaryotic metabolism and metabolic-related disease states is profound. ACCs catalyze the formation of malonyl-CoA by ATP-dependent carboxylation of acetyl-CoA. In humans, the two isoforms of ACC exhibit highly regulated, tissue-specific patterns of expression, with ACC1 being present in lipogenic tissues such as liver and adipose, and ACC2 being
Read more
No Comments

ABC Transporter MsbA Inhibitors Discovered to Help Fight Against Gram-Negative Bacteria

ABC Transporter Inhibitor Klebsiella Treatment
Gram-negative bacterial pathogens pose grave dangers in clinical and environmental settings alike. They include foodborne disease pathogens such as E. coli 0157:H7, waterborne pathogens such as Vibrio cholera, vector-borne pathogens such as Yersinia pestis, and a disturbingly large number of Gram-negative pathogens that now display resistance to multiple antimicrobial agents.1 Resistant Gram-negative pathogens include some
Read more
No Comments

Minding the Membrane: Powerful Approach to Interrogate Molecular Events in Ras-PI3K Interactions

It has been 30 years since the lipid signaling molecule phosphatidylinositol 3,4,5-trisphosphate (PIP3) was first identified¹, and its role as a key regulator of cell growth and survival was recognized in the earliest investigations into this molecule.² Class IA phosphoinositide 3-kinases (PI3Ks) generate PIP3. The inappropriate activation of this pathway has grave consequences in many
Read more
No Comments

Transcreener Assay Helps Find New Approach to C. difficile

Clostridium difficile – One of the Deadliest Enemies in Hospitals There are half a million reasons to consider Clostridium difficile as “Enemy Number 1” for public health. That’s because the annual cases of C. difficile, or C diff, infection now top 500,000 per year in the U.S.—resulting in more than 29,000 deaths per year. Worse
Read more
No Comments

Transcreener ADP Assay Aids in Discovery of RIPK2 Inhibitors for Autoinflammation

When the body responds to a bacterial pathogen, fragments of bacterial peptidoglycan alert a human host to the presence of a microbial invader. A receptor named NOD2 recognizes the peptidoglycans and sounds the alarm, initiating immune responses by causing the production of pro-inflammatory cytokines via NF-κB and MAP kinase pathways 1. In this manner, NOD2
Read more
No Comments

Newly Patented Aurora A Kinase Inhibitor a Promising Contender for Cancer Treatment

Aurora A Kinase in Cancer Drug Development Aurora A Kinase, along with -B and -C, are members of a family of serine/threonine protein kinases that play critical roles in coordinating mitosis, including establishment of the mitotic spindle, centrosome duplication, centrosome separation as well as maturation, chromosomal alignment, spindle assembly checkpoint, and cytokinesis. The enzyme’s role
Read more
No Comments

Using the Transcreener® GDP Assay to Discern the Truth about Dynamin Inhibitors

Imagine viewing the plasma membrane of a cell from an interior perspective, with a front-row seat to the process by which substances enter the cell. Over in one corner, the plasma membrane begins to bulge inward, forming a sphere stretching toward you with a droplet-shaped neck on the opposite side that remains connected to the
Read more
No Comments

Transcreener® Assays Help Feed Epigenetics Drug Pipeline Down Under

Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK, recently announced a licensing agreement with Merck (MSD) to develop and commercialize protein arginine methyltransferase 5 (PRMT5) inhibitors. CRT, a subsidiary of Cancer Research UK, entered into this agreement with MSD (Germany) on behalf the Australian Cooperative Research Center for Cancer Therapeutics
Read more
No Comments

Success Story: Development of a High Throughput Screening Assay to Identify Inhibitors of the de novo Purine Biosynthetic Pathway

Slides available here. Our mission at BellBrook Labs is to accelerate drug discovery by producing truly enabling high throughput screening tools for protein targets and phenotypic cellular assays.  Like our customers, we’re driven by a desire to make a real impact on improving human health. We’re proud of our products and the innovative work our
Read more
No Comments